Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
Three months after Biogen announced its $5.6bn buyout of rare disease specialist Apellis Pharmaceuticals, the former has decided to cull…
29 Jun 2026
FDA issues complete response letter to Sobi’s NASP for gout
Swedish Orphan Biovitrum (Sobi) has received a complete response letter from the US Food and Drug Administration (FDA) regarding its biologics licence application for nanoencapsulated sirolimus plus pegadricase (NASP), an…
29 Jun 2026
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
Eli Lilly and Company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Jaypirca (pirtobrutinib) to treat…
26 Jun 2026
Immunai and Boehringer partner to identify T-cell targets
Immunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases. The initial phase of the partnership, valued at up to $15m…
26 Jun 2026
Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval
Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug, with that forecast having just become more likely following a…
26 Jun 2026
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201, leaving the biopharma company poised to push the drug’s clinical…
26 Jun 2026
Ionis grants Recordati rights to zilganersen for Alexander disease
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US. Ionis…